news
Gene-editing for sickle cell and beta-thalassemia is here, approved
The Lancet editorial confirmed the launch of Casgevy/exa-cel, a gene-editing therapy, for sickle cell disease and β-thalassemia, citing remarkable patient results. This treatment, first used in 2019, has now expanded to other conditions like leukemia and transthyretin amyloidosis. It's a huge step for targeted disease treatment beyond just managing symptoms.
The Lancet editorial confirmed the launch of Casgevy/exa-cel, a gene-editing therapy, for sickle cell disease and β-thalassemia, citing remarkable patient results. This treatment, first used in 2019, has now expanded to other conditions like leukemia and transthyretin amyloidosis. It's a huge step for targeted disease treatment beyond just managing symptoms.
The architecture take
I'm still thinking about Victoria Gray, the first patient to get Casgevy for sickle cell disease. She described her pain like being hit by a freight train. That's a body in crisis, deeply dysregulated. Now, she says she can dream again without limitations. That's not just fixing a blood disorder; it's restoring her nervous system's capacity, changing her entire state. This isn't some distant biotech dream anymore. The CRISPR-based therapy, exa-cel, literally edits DNA in her cells to produce healthy hemoglobin. This approval changes the game from symptom management to root-cause intervention for genetic conditions. It’s a massive signal to the market, pushing R&D into other gene-editing applications beyond rare diseases, especially for conditions with a clear genetic marker. Watch how quickly this technology scales and what it means for other chronic, hard-to-treat conditions. It's a fundamental shift in what's possible.